About Alpha Teknova, Inc.
https://www.teknova.comAlpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.
CEO
Stephen Gunstream
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
UBS GROUP AG
Shares:1.5M
Value:$5.81M
BALYASNY ASSET MANAGEMENT L.P.
Shares:987.23K
Value:$3.82M
ROUBAIX CAPITAL, LLC
Shares:833.82K
Value:$3.23M
Summary
Showing Top 3 of 72
About Alpha Teknova, Inc.
https://www.teknova.comAlpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10.45M ▲ | $7.22M ▼ | $-4.29M ▼ | -41% ▼ | $-0.08 ▼ | $-2.43M ▼ |
| Q2-2025 | $10.29M ▲ | $7.37M ▼ | $-3.57M ▲ | -34.7% ▲ | $-0.07 ▲ | $-1.8M ▲ |
| Q1-2025 | $9.79M ▲ | $7.97M ▲ | $-4.64M ▲ | -47.42% ▲ | $-0.09 ▲ | $-3.38M ▲ |
| Q4-2024 | $9.27M ▼ | $7.76M ▲ | $-5.72M ▲ | -61.73% ▲ | $-0.11 ▲ | $-3.98M ▲ |
| Q3-2024 | $9.58M | $7.52M | $-7.57M | -79% | $-0.17 | $-5.76M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.2M ▼ | $107.63M ▼ | $34.98M ▲ | $72.65M ▼ |
| Q2-2025 | $24M ▼ | $110.49M ▼ | $34.43M ▼ | $76.06M ▼ |
| Q1-2025 | $26.27M ▼ | $113.99M ▼ | $35.39M ▼ | $78.61M ▼ |
| Q4-2024 | $30.4M ▼ | $118.77M ▼ | $36.38M ▼ | $82.39M ▼ |
| Q3-2024 | $31.69M | $124.1M | $36.83M | $87.27M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.29M ▼ | $-1.88M ▲ | $1.64M ▼ | $168K ▲ | $-72K ▲ | $-2.27M ▲ |
| Q2-2025 | $-3.57M ▲ | $-2.1M ▲ | $2.03M ▼ | $-28K ▲ | $-101K ▲ | $-2.31M ▲ |
| Q1-2025 | $-4.64M ▲ | $-4.1M ▼ | $3.82M ▲ | $-52K ▲ | $-331K ▲ | $-4.31M ▼ |
| Q4-2024 | $-5.72M ▲ | $-936K ▲ | $-1.41M ▲ | $-87K ▼ | $-2.44M ▲ | $-1.5M ▲ |
| Q3-2024 | $-7.57M | $-2.06M | $-25.76M | $15.37M | $-12.45M | $-2.39M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Clinical Solutions | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Lab Essentials | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Other Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Stephen Gunstream
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
UBS GROUP AG
Shares:1.5M
Value:$5.81M
BALYASNY ASSET MANAGEMENT L.P.
Shares:987.23K
Value:$3.82M
ROUBAIX CAPITAL, LLC
Shares:833.82K
Value:$3.23M
Summary
Showing Top 3 of 72